Prevention - Finasteride USA Prostate cancer prevention trial 1993 – 2003 18,882 men with PSA < 3 and normal DRE enrolled.
{"Image DocumentName": "Prevention - Finasteride", "Image ImageDescription": "USA Prostate cancer prevention trial 1993 \u2013 ,882 men with PSA < 3 and normal DRE enrolled. 5 mg of Finasteride per day or placebo. Study closed 15 months before planned closure because overwhelming evidence that. the primary end point (prostate cancer prevalence) had been met % reduction in prostate cancer risk. Increased proportion of high grade prostate cancers diagnosed from 1.1% to. 1.8%raised (and more likely cause of early closure). Prompted FDA warning. Subsequent analysis suggests finasteride improved sensitivity of PSA for cancer. overall, and especially for high grade cancer . The Influence of Finasteride on the Development of Prostate Cancer. Thompson et al NEJM 2003; 349: 215.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}